Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1Phase 2/3 1

Status

Unknown 6Recruiting 4Not yet recruiting 4Completed 3Active not recruiting 2

Sponsor Class

OTHER 48INDUSTRY 33OTHER_GOV 4NETWORK 3NIH 2

Study Type

Interventional 4

Sponsor

Cancer Type

Gynecologic 4

Conditions

Breast Neoplasms 45Neoplasms 27Uterine Cervical Neoplasms 24Prostatic Neoplasms 21Carcinoma, Non-Small-Cell Lung 20Colorectal Neoplasms 19Stomach Neoplasms 18Carcinoma, Hepatocellular 16Multiple Myeloma 14Ovarian Neoplasms 11Recurrence 10Pancreatic Neoplasms 10Esophageal Squamous Cell Carcinoma 10Esophageal Neoplasms 9Leukemia, Myeloid, Acute 8Endometrial Neoplasms 8Lymphoma 7Lung Neoplasms 7Brain Neoplasms 7Liver Neoplasms 6Leukemia 6Disease 6Carcinoma, Ovarian Epithelial 6Triple Negative Breast Neoplasms 5Small Cell Lung Carcinoma 5Rectal Neoplasms 5Papillomavirus Infections 5Colonic Neoplasms 5Urinary Bladder Neoplasms 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4

Interventions

Poly(ADP-ribose) Polymerase Inhibitors 2Bevacizumab 2taxane 1olaparib 1niraparib 1Surgical Procedures, Operative 1Neoadjuvant Therapy 1Maintenance 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Recruiting × OTHER_GOV × Fallopian Tube Neoplasms × Clear all
NCT07472140 2026-03-16

PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer

N.N. Alexandrov National Cancer Centre

Phase 2/3 Recruiting
120 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05236686 2025-11-19

Survival Effect of Hepato-celiac Lymphadenectomy In Primary or Relapsed Ovarian Cancer

Shanghai Gynecologic Oncology Group

Phase NA Recruiting
94 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Lymphatic Metastasis, Ovarian Neoplasms

NCT05200260 2025-02-10

Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer

Shanghai Gynecologic Oncology Group

Phase 2 Recruiting
220 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03983226 2022-03-18

Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial)

Shanghai Gynecologic Oncology Group

Phase 2 Recruiting
167 enrolled
Gynecologic

Fallopian Tube Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡